xemilofiban has been researched along with Coronary Disease in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (58.33) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anders, RJ; Anderson, LC; Hantsbarger, G; Higby, NA; Kereiakes, DJ; Kleiman, NS; McDonald, S; Runyon, JP | 1 |
| Kikuchi, S; Kondo, K; Nakashima, M; Nishiyama, H; Umemura, K | 1 |
| Anders, RJ; Broderick, TM; Ferguson, JJ; Hantsbarger, G; Higby, NA; Kereiakes, DJ; Kleiman, N; Martin, LH; McDonald, S; Runyon, JP | 1 |
| Gawaz, M; Neumann, FJ; Schömig, A | 1 |
| Teirstein, PS | 1 |
| Morris, DC | 1 |
| Ferguson, JJ | 1 |
| Alexander, J; Anders, R; Dreiling, R; Gong, J; Kleiman, J; Knudtson, M; O'Neill, WW; Roecker, EB; Serruys, P; Timmis, GC; van der Zwaan, C; van Es, GA | 1 |
| Jang, IK; Sabatine, MS | 1 |
| Bhatt, DL; Chew, DP | 1 |
| Bhatt, DL; Chew, DP; Sapp, S; Topol, EJ | 1 |
| Davis, CJ; Lowry, DR; McKenzie, ME; Nair, GV; Serebruany, VL | 1 |
5 review(s) available for xemilofiban and Coronary Disease
| Article | Year |
|---|---|
[Platelet membrane glycoproteins as site of pharmacological intervention in the treatment of coronary disease].
Topics: Abciximab; Acetates; Alkynes; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Binding Sites; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Coronary Disease; Double-Blind Method; Eptifibatide; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Platelet Membrane Glycoproteins; Randomized Controlled Trials as Topic; Receptors, Antigen, B-Cell; Receptors, Cell Surface; Time Factors; Tirofiban; Tyrosine | 1997 |
The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.
Topics: Abciximab; Acetates; Acute Disease; Administration, Oral; Alanine; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Benzamidines; Coronary Disease; Eptifibatide; Hemorrhage; Humans; Immunoglobulin Fab Fragments; Myocardial Infarction; Oximes; Peptides; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic; Stents; Syndrome; Thrombocytopenia; Thrombolytic Therapy; Tirofiban; Tyrosine | 2000 |
Oral glycoprotein IIb/IIIa antagonists in coronary artery disease.
Topics: Administration, Oral; Alanine; Benzamidines; Coronary Disease; Humans; Integrins; Oximes; Piperidines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic | 2001 |
Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
Topics: Administration, Oral; Alanine; Aspirin; Benzamidines; Clinical Trials, Phase III as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemorrhage; Humans; Incidence; Multicenter Studies as Topic; Myocardial Infarction; Oximes; Piperidines; Platelet Glycoprotein GPIIb-IIIa Complex; Pyrrolidines; Randomized Controlled Trials as Topic | 2001 |
Aspirin in patients with coronary artery disease: is it simply irresistible?
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Benzamidines; Clinical Trials as Topic; Clopidogrel; Coronary Disease; Cyclooxygenase Inhibitors; Diabetes Complications; Dipyridamole; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Endothelium, Vascular; Fibrinolytic Agents; Humans; Immunoglobulin Fab Fragments; Oximes; Piperidines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Prospective Studies; Randomized Controlled Trials as Topic; Stroke; Thrombosis; Thromboxane-A Synthase; Ticlopidine; Vasodilator Agents | 2001 |
3 trial(s) available for xemilofiban and Coronary Disease
| Article | Year |
|---|---|
Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention.
Topics: Abciximab; Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Benzamidines; Coronary Disease; Dose-Response Relationship, Drug; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex | 1996 |
Sustained platelet glycoprotein IIb/IIIa blockade with oral xemilofiban in 170 patients after coronary stent deployment.
Topics: Abciximab; Administration, Oral; Aged; Antibodies, Monoclonal; Aspirin; Benzamidines; Coronary Disease; Dose-Response Relationship, Drug; Female; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Single-Blind Method; Stents; Thrombosis; Ticlopidine | 1997 |
Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic Events.
Topics: Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Benzamidines; Coronary Artery Bypass; Coronary Disease; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Stents; Thrombocytopenia | 2000 |
4 other study(ies) available for xemilofiban and Coronary Disease
| Article | Year |
|---|---|
Inhibitory effect of a novel orally active GP IIb/IIIa inhibitor, SC-54684A on intimal thickening in the guinea pig femoral artery.
Topics: Angioplasty, Balloon, Coronary; Animals; Aspirin; Benzamidines; Cell Movement; Cells, Cultured; Coronary Disease; Disease Models, Animal; Drug Evaluation, Preclinical; Endothelium, Vascular; Femoral Artery; Guinea Pigs; Male; Microscopy, Electron, Scanning; Muscle, Smooth, Vascular; Photochemistry; Plasminogen Activators; Platelet Adhesiveness; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Reactive Oxygen Species; Recombinant Proteins; Recurrence; Rose Bengal | 1996 |
Early clinical results with the new oral glycoprotein IIb/IIIa agents.
Topics: Benzamidines; Clinical Trials as Topic; Coronary Disease; Humans; Oximes; Piperidines; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex | 1999 |
Results from late-breaking clinical trials sessions at ACCIS '99 and ACC '99. American College of Cardiology.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticholesteremic Agents; Anticoagulants; Benzamidines; Coronary Angiography; Coronary Artery Bypass; Coronary Disease; Humans; Immunoglobulin Fab Fragments; Myocardial Ischemia; Myocardial Revascularization; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Simvastatin; Stents; Thrombolytic Therapy; Time Factors; Tissue Plasminogen Activator; Treatment Outcome | 1999 |
Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology.
Topics: Abciximab; Alanine; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; Antibodies, Monoclonal; Aspirin; Benzamidines; Biphenyl Compounds; Cardiology; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Disease; Dalteparin; Defibrillators, Implantable; Double-Blind Method; Enalapril; Endothelial Growth Factors; Fatty Acids, Omega-3; Guanidines; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulin Fab Fragments; Laser Therapy; Lymphokines; Metoprolol; Multicenter Studies as Topic; Myocardial Revascularization; Platelet Aggregation Inhibitors; Pyrrolidines; Randomized Controlled Trials as Topic; Simvastatin; Sodium-Hydrogen Exchangers; Stents; Sulfones; Thrombolytic Therapy; Ticlopidine; Tissue Plasminogen Activator; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vitamin E | 1999 |